Budde, Holger

[["dc.bibliographiccitation.firstpage","1127"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1133"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:22:22Z"],["dc.date.available","2018-11-07T10:22:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Graft-versus-host disease (GvHD) still belongs to the major challenges after allogeneic hematopoietic stem cell transplantation (HSCT). Immune-suppressive therapy against GvHD is a double-edged sword due to risk of infections and relapse. The ability to adapt prophylactic treatment according to the probability of severe GvHD would be an essential advantage for the patients. We analyzed different biomarkers for their potential to predict the development of GvHD in 28 patients who underwent allogeneic HSCT. Blood was taken once directly after hematopoietic engraftment. In this study, patients were monitored for 12 months after HSCT for the occurrence of acute GvHD or acute/chronic GvHD overlap syndrome. Soluble IL-2 receptor and CD4/CD8 T cell ratio were independently associated with the occurrence of GvHD in the observation period. However, the largest area under the receiver operating characteristic curve with 0.90 was observed when a 5-parameter biomarker score based on CD4(+) T cells, CD8(+) T cells, CD19(-) CD21(+) precursor B cells, CD4/CD8 T cell ratio, and soluble IL-2 receptor was used to predict GvHD. In addition, CD8(+) T cell levels above 2.3% of all mononuclear cells after engraftment may predict relapse-free survival at least for 12 months. In summary, we found a new biomarker panel for prediction of GvHD which is featured by established laboratory assays and high statistical significance. In order to introduce the biomarker panel into routine clinical protocols, we suggest performing a larger multi-center study."],["dc.identifier.doi","10.1007/s00277-017-2999-5"],["dc.identifier.isi","000403078900008"],["dc.identifier.pmid","28447161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42255"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","345"],["dc.identifier.isi","000400973300016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42465"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","AN ALTERNATIVE SETUP FOR EXTRACORPOREAL PHOTOPHERESIS: 8-METHOXYPSORALEN AND UVA-TREATED LEUKOCYTES FROM ALLOGENEIC DONORS IMPROVE GRAFT VERSUS HOST DISEASE IN MICE"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","362"],["dc.identifier.isi","000400973300051"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42466"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","SCREENING FOR A BIOMARKER PANEL FOR PREDICTION OF GRAFT VERSUS HOST DISEASE IN HUMANS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","465"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","472"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Sorns, Marie-Sophie"],["dc.contributor.author","Welker, Pia"],["dc.contributor.author","Licha, Kai"],["dc.contributor.author","Wolff, Hendrik"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:18:30Z"],["dc.date.available","2018-11-07T10:18:30Z"],["dc.date.issued","2016"],["dc.description.abstract","Graft-versus-host disease (GvHD) is a severe immune reaction commonly occurring after hematopoietic stem cell transplantation. The outcome of patients who do not respond to the currently used immunosuppressive drugs is poor, thus there is an urgent need for the evaluation of new therapies. Heparin has a well-known anti-inflammatory effect and heparin analogues with a low anticoagulant effect are interesting candidates as new anti-inflammatory drugs. We explored the therapeutic potential of dendritic polyglycerol sulfates (dPGS), a novel class of heparin derivatives, on murine acute GvHD in vivo. The therapeutic effect of dPGS on murine GvHD was more intense after intravenous application compared to subcutaneous injection. An increased survival rate and improved clinical scores were observed in mice treated with 5 mg/kg once a week. In these animals, there was a reduction in the percentage of CD4(+) and CD8(+) T cells, which are the main effectors of GvHD. In addition, dPGS treatment decreased the number of tumor necrosis factor alpha (TNF alpha)-producing T cells. Increasing the dose of dPGS reversed the positive effect on survival as well as the clinical score, which indicates a small therapeutic range. Here, we report for the first time that dPGS have a significant immunosuppressive in vivo effect in a mouse model of severe acute GvHD. Therefore, we propose to study dPGS as promising candidates for the development of potential new drugs in the treatment of steroid-refractory GvHD patients first in larger animals and later in humans."],["dc.identifier.doi","10.1007/s00277-015-2565-y"],["dc.identifier.isi","000371605300013"],["dc.identifier.pmid","26634847"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41459"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Dendritic polyglycerol sulfate attenuates murine graft-versus-host disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1073"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Nucleosides, Nucleotides & Nucleic Acids"],["dc.bibliographiccitation.lastpage","1081"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Rau, Anne Lone"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias J."],["dc.date.accessioned","2020-12-10T18:15:14Z"],["dc.date.available","2020-12-10T18:15:14Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1080/15257770.2020.1755042"],["dc.identifier.eissn","1532-2335"],["dc.identifier.issn","1525-7770"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74785"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Apoptosis induction by miR-19b inhibition: does it show therapeutic potential for leukemia?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","632"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.lastpage","638"],["dc.bibliographiccitation.volume","104"],["dc.contributor.author","Dauber, Eva-Maria"],["dc.contributor.author","Mayr, Wolfgang R."],["dc.contributor.author","Hustinx, Hein"],["dc.contributor.author","Schönbacher, Marlies"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Legler, Tobias J."],["dc.contributor.author","König, Margit"],["dc.contributor.author","Haas, Oskar A."],["dc.contributor.author","Fritsch, Gerhard"],["dc.contributor.author","Körmöczi, Günther F."],["dc.date.accessioned","2020-12-10T18:44:18Z"],["dc.date.available","2020-12-10T18:44:18Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3324/haematol.2018.201293"],["dc.identifier.eissn","1592-8721"],["dc.identifier.issn","0390-6078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78401"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Somatic mosaicisms of chromosome 1 at two different stages of ontogenetic development detected by Rh blood group discrepancies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","803"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Vox Sanguinis"],["dc.bibliographiccitation.lastpage","810"],["dc.bibliographiccitation.volume","113"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Reichardt, Holger M."],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias J."],["dc.date.accessioned","2020-12-10T18:36:32Z"],["dc.date.available","2020-12-10T18:36:32Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/vox.12723"],["dc.identifier.issn","0042-9007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76662"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","An alternative for extracorporeal photopheresis: 8-methoxypsoralen and UVA-treated leucocytes from allogeneic donors improve graft-versus-host disease in mice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2127"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Development"],["dc.bibliographiccitation.lastpage","2132"],["dc.bibliographiccitation.volume","137"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Schmitt, Sebastian"],["dc.contributor.author","Fitzner, Dirk"],["dc.contributor.author","Opitz, Lennart"],["dc.contributor.author","Salinas-Riester, Gabriela"],["dc.contributor.author","Simons, Mikael"],["dc.date.accessioned","2018-11-07T08:41:36Z"],["dc.date.available","2018-11-07T08:41:36Z"],["dc.date.issued","2010"],["dc.description.abstract","The generation of myelinating cells in the central nervous system requires the initiation of specific gene expression programs in oligodendrocytes. We reasoned that microRNAs (miRNAs) could play an important role in this process by regulating crucial developmental genes. Microarray profiling of cultured oligodendrocytes identified the miR-17-92 miRNA cluster as highly enriched in oligodendrocytes. We specifically deleted the miR-17-92 cluster in oligodendrocytes using 2',3'-cyclic nucleotide 3' phosphodiesterase (Cnp)-Cre mice. Absence of miR-17-92 leads to a reduction in oligodendrocyte number in vivo and we find that the expression of these miRNAs in primary cultures of oligodendrocyte precursor cells promotes cell proliferation by influencing Akt signaling. Together, these results suggest that the miRNA pathway is essential in determining oligodendroglial cell number and that the miR-17-92 cluster is crucial in this process."],["dc.description.sponsorship","ERC; EMBO YIP; Boehringer Ingelheim Fonds"],["dc.identifier.doi","10.1242/dev.050633"],["dc.identifier.isi","000278559900006"],["dc.identifier.pmid","20504959"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19507"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Company Of Biologists Ltd"],["dc.relation.issn","0950-1991"],["dc.title","Control of oligodendroglial cell number by the miR-17-92 cluster"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]